



Modifications in Therapeutic Oligonucleotides Improving the Delivery

Ilya Dovydenko, Alya Venyaminova, Dmitrii Pyshnyi, Ivan Tarassov, Nina Entelis

► To cite this version:

Ilya Dovydenko, Alya Venyaminova, Dmitrii Pyshnyi, Ivan Tarassov, Nina Entelis. Modifications in Therapeutic Oligonucleotides Improving the Delivery. Stefan Jurga; Volker A. Erdmann; Jan Barciszewski. Modified Nucleic Acids in Biology and Medicine, Springer International Publishing, pp.319-337, 2016, RNA Technologies, 10.1007/978-3-319-34175-0_14 . hal-03561747

HAL Id: hal-03561747

<https://hal.science/hal-03561747>

Submitted on 21 Feb 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Modifications in Therapeutic Oligonucleotides Improving the Delivery

Ilya Dovydenko, Alya Venyaminova, Dmitrii Pyshnyi, Ivan Tarassov, and Nina Entelis

Contents

- 1 Introduction: Nucleic Acids' Delivery Systems
 - 2 Carrier-Free Targeting Systems
 - 2.1 Nucleic Acids' Conjugation with Targeting Ligands
 - 2.2 Conjugates with Carbohydrates
 - 2.3 Conjugates with Peptides and Aptamers
 - 2.4 Lipid-Containing Conjugates
 - 3 Modifications Improving the Stability of Nucleic Acids
 - 4 Modifications of the Therapeutic RNA Imported into Human Mitochondria
 - 5 Conclusion and Future Prospects .
- References

Abstract Oligonucleotides are increasingly used in clinical applications. RNA-based therapeutics include inhibitors of mRNA translation, agents of RNA interference, ribozymes, and aptamers targeting various molecular targets. Challenges with the delivery, specificity, and stability of these therapeutics have spawned the development of chemically modified oligonucleotides. In this chapter, we will describe modifications improving delivery and stability of RNA molecules in human cells. Because the most of the cell transfection methods using oligonucleotide complexes with cationic lipids revealed to be toxic, specific modifications and various conjugates have been recently developed to promote the carrier-free

I. Dovydenko

UMR Génétique Moléculaire, Génomique, Microbiologie (GMGM), Strasbourg University-CNRS, Strasbourg 67084, France

Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia

A. Venyaminova • D. Pyshnyi

Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia

I. Tarassov • N. Entelis (✉)

UMR Génétique Moléculaire, Génomique, Microbiologie (GMGM), Strasbourg University-CNRS, Strasbourg 67084, France

e-mail: n.entelis@unistra.fr

cellular uptake of therapeutic oligonucleotides. Nucleic acids (NA) are relatively unstable in cytosol due to a plethora of nucleases; therefore, various modifications can be introduced to design nuclease-resistant molecules. These modifications should not interfere with the therapeutic activity and intracellular localization of the oligonucleotides. The influence of nucleotide modifications on the siRNA efficiency and on the anti-replicative activity of therapeutic RNA imported into human mitochondria is discussed.

Keywords Delivery • Oligonucleotide therapeutics • Lipophilic conjugates • Modified oligonucleotides • Mitochondrial diseases • Anti-replicative RNA

1 Introduction: Nucleic Acids' Delivery Systems

Synthetic oligonucleotides and their conjugates are widely used in various fields of molecular biology, nanobiotechnology, and medicine as tools for fundamental and applied research, as well as promising drugs for diagnosis and treatment of viral and genetic diseases, cancer, and other diseases of humans and animals (Ginn et al. 2013; Tan et al. 2011). Development of oligonucleotides as potential therapeutic agents is limited by low efficiency of penetration into target cells due to their large size, negative charge, and low stability. Many systems of gene targeting have been developed to overcome these barriers. Delivery vectors can be divided into the two major groups: viral and nonviral systems (Kay 2011). Each type has its own advantages and disadvantages. Systems based on viral vectors have efficient mechanisms for entering the cell, escaping endosomal entrapment, and translocating gene cargo to the nucleus. Despite of a high efficiency of targeting, several limitations are associated with viral systems: insertional mutagenesis, immune response to viral proteins, tumorigenesis, and cytotoxic effects (Thomas et al. 2003; Walther and Stein 2000).

The shortcomings in viral vectors stimulated development of nonviral delivery carriers, which can be readily synthesized and modified to facilitate biocompatibility. Improving of nonviral delivery systems relies on the detailed understanding of the barriers associated with the nucleic acids targeting into cells. The successful system for nucleic acids' (NA) delivery should meet a number of requirements: biocompatibility and low cytotoxicity, resistance to nuclease activity, possibility of endosomal escape, and capability of entering the appropriate cellular compartment.

Mammalian cells internalize extracellular macromolecules by the endocytosis leading to formation of vesicle-like structures that fuse with early endosomes (De Haes et al. 2012). Thus, the efficacy of transfection and the expected effect depend on both the ability of a carrier to efficiently deliver the NA cargo with minimal toxicity and its potential to overcome the endosomal compartmentalization (Huotari and Helenius 2011). To facilitate NA escape into the cytosol, various compounds have been used in combination with the delivery vectors.

Endosomolytic agents vary in type (natural or synthetic compounds) as well as in their mechanisms of action, which include the endosomal membrane destabilization (TAT HIV, KALA, or GALA peptides), pore formation (e.g., listeriolysin O toxin produced by *Listeria monocytogenes*, gp41HIV protein), and endosomal disruption via the “proton sponge” mechanism (e.g., PEI, ammonium chloride, chloroquine, methylamine) (Varkouhi et al. 2011).

Nonviral delivery systems can be carrier-mediated or carrier-free. The carrier-mediated NA targeting systems can be further subdivided into the three main groups:

- (a) Polymeric systems, in which NA form complex with a polymer through charge interactions between the positive groups of the polymer and the negatively charged NA (Oliveira et al. 2015)
- (b) Lipidic systems, in which cationic lipids interact with negatively charged NA and condensate or encapsulate them (Balazs and Godbey 2011)
- (c) Inorganic carriers involving various materials such as gold nanoparticles, silica, and carbon nanotubes, which can bind NA through different mechanisms (Dizaj et al. 2014)

In this chapter we will describe another approach for delivery of oligonucleotides, which consists in conjugation of NA molecules with targeting ligands.

2 Carrier-Free Targeting Systems

2.1 Nucleic Acids' Conjugation with Targeting Ligands

The transporting molecule should be capable of binding to the cell surface or to specific receptors on it and inducing endocytosis (Juliano et al. 2013). The ligand molecule can be attached to NA directly or through a linker. Depending on the type of oligonucleotide and its purpose, the linker can be connected via the 2'-, 3'-, or 5'-terminus, the C5 atom of pyrimidine bases, the C8 atom of adenine, the exocyclic amino group of guanine, or an internucleoside phosphate (Winkler 2013). Conjugated NA cargo needs additional chemical modifications shielding it from nucleases (see Sect. 3 for details). For most carrier-free systems, the endosomal escape is passive, which reduces the efficiency of transfection; thus, there is a necessity to use additional compounds to promote the release of oligonucleotides from endosomes before they are degraded and recycled. However, the simplicity of design and the small size, in comparison with nanoparticles, ensure a lower toxicity and a better biodistribution of NA conjugates. Carriers with sizes larger than 5 nm can only be used for NA delivery to certain types of tumors and to normal tissues with fenestrated endothelia, such as the liver and spleen, whereas conjugates can also reach many other types of tissues (Juliano et al. 2009).

Various delivery systems through covalent attachment of addressing ligands to the NA cargo have been developed: carbohydrate–NA conjugates, peptide–NA conjugates, antibody–NA conjugates (Uckun et al. 2013), aptamer conjugates, and lipid–NA conjugates. Here, we will briefly characterize the main types of conjugates and provide a more detailed analysis of lipophilic molecules.

2.2 Conjugates with Carbohydrates

It had been demonstrated that the asialoglycoprotein receptor located on the surface of hepatocytes can bind diverse chemotherapeutic agents, including galactose glycoproteins, and helps their internalization by endocytosis (Stockert 1995). This permitted the use of carbohydrate-based vectors for addressed NA delivery. For instance, 5⁰-glycoconjugates of oligonucleotides have demonstrated excellent cell-type specificity and cellular uptake in the nanomolar concentration range (Biessen et al. 1999). Triantennary N-acetyl galactosamine conjugates (Fig. 1) facilitate the targeted delivery of siRNAs and antisense oligonucleotides to hepatocytes in vivo (Nair et al. 2014; Prakash et al. 2014).

2.3 Conjugates with Peptides and Aptamers

Peptides used for NA delivery can be divided into the two classes. The first group includes cell-targeting peptides, specific ligands for surface receptors overexpressed in diseased cells (Juliano et al. 2013; McGuire et al. 2014; Vives et al. 2008). For instance, bombesin peptide (a ligand for the gastrin-releasing peptide receptor) and a specific peptide for the IGF1R receptor overexpressed in




Fig. 1 Triantennary N-acetyl galactosamine-nucleic acid conjugate

breast cancer were conjugated with an siRNA and an antisense oligonucleotide, respectively, for targeted delivery (Cesarone et al. 2007; Ming et al. 2010). The second group comprises the cell-penetrating peptides (CPPs). These peptides are short, amphiphilic, and enriched with the basic amino acids. CPPs can enter cells by two ways, either via endocytosis through electrostatic interactions with negatively charged glycosaminoglycans, similar to cationic polymers (Juliano et al. 2008), or through membrane translocation. The choice of the entry pathway is dependent on the CPP sequence, concentration, and the temperature (Boisguerin et al. 2015). CPPs can also promote the endosomal escape.

Aptamers are small nucleic acids that fold into a well-defined structure, which determines their affinity and specificity for target molecules. They can be selected from pools of randomized sequences by SELEX (Systematic Evolution of Ligands by Exponential Enrichment) approach (Tuerk and Gold 1990). Aptamers can be evolved to bind small molecules but also nucleic acids, carbohydrates, and soluble or membrane proteins. For instance, so-called escort aptamers recognize cell surface receptors specific for the certain cell type and can be used for the targeted delivery of therapeutic agents. One of the most known aptamers of this type is the 2^0 -F-RNA aptamer against prostate-specific membrane antigen (PSMA). After binding to its target, the anti-PSMA aptamer can be internalized; therefore, this escort aptamer is widely used now as a delivery vehicle for a number of antitumor drugs, including siRNAs and shRNAs. A comprehensive overview of the therapeutic nucleic acids delivery strategies using aptamers can be found in recently published reviews (Aaldering et al. 2015; Davydova et al. 2011; Ming and Laing 2015; Tan et al. 2011; Zhou and Rossi 2011).

2.4 Lipid-Containing Conjugates

One of the most popular methods of delivery of conjugated oligonucleotides is the use of lipids. Various lipophilic molecules have been conjugated to oligonucleotides, including phospholipids, fatty acids, bile acids (e.g., cholic acid), cholesterol, and fat-soluble vitamins (as α -tocopherol, folic acid) (Bhat et al. 1999; Guzaev et al. 2002; Raouane et al. 2012). The structures of these compounds are shown in Fig. 2. Among those, cholesterol, studied by various groups for the past 25 years since the pioneering work of Letsinger et al. (1989), is by far the most extensively characterized addressing agent.

Cholesterol is an essential lipid of cell membranes of many eukaryotes, which make it attractive for delivery of various therapeutic molecules. Intravenous administration of cholesterol-containing siRNA conjugates resulted in significant levels of their accumulation in liver, heart, kidney, adipose, and lung tissues (Soutschek et al. 2004). In another study, accumulation of a cholesterol-conjugated siRNA in brain cells upon intrastriatal injection has been demonstrated (DiFiglia et al. 2007). These and other studies show that cholesterol conjugation significantly improves delivery of NA. Cellular uptake of cholesterol-conjugated oligonucleotides in vivo




Fig. 2 Various lipophilic molecules used for conjugation with oligonucleotides

depends on the complex formation between the conjugates and the high-density or low-density lipoproteins circulating in the bloodstream. Binding of the complexes to the lipoprotein receptors leads to the uptake of the conjugates by the various tissues (Wolfrum et al. 2007).

Conjugates of oligonucleotides with cholesterol have been developed by many research groups, wherein attachment to an oligonucleotide was performed mainly through either the 5'- or the 3'-termini. Cholesterol can be attached through the unique hydroxyl group of the steroid either directly (MacKellar et al. 1992; Seo et al. 2006) or via various aliphatic linkers. Examples of linear linkers are molecules based on diamines (Letsinger et al. 1989), amino alcohols with various lengths of aliphatic chain (Lorenz et al. 2004; Petrova et al. 2011), and polyethylene glycol (Kubo et al. 2007) (Fig. 3).

Another approach to the synthesis of cholesterol-conjugated oligonucleotides is introducing the steroid residue at the 5'- or 3'-terminus of the oligonucleotide chain through branched linkers containing several reactive groups. The compounds used




Fig. 3 Cholesterol conjugated with oligonucleotides directly (a), through linear linkers based on ethylenediamine (b), amino alcohols with various lengths of aliphatic chain (c), or polyethylene glycol (d)

as the branched linkers include glycerol (Ueno et al. 2008; Vu et al. 1993), 2-aminobutyl-1,3-propanediol (Rump et al. 1998), L-hydroxyproline (Manoharan et al. 2005; Reed et al. 1991), lysine (Stetsenko and Gait 2001), serine (Chaltin et al. 2005), and serinol (Manoharan et al. 2005) (Fig. 4).

A cholesterol residue may negatively affect the therapeutic effect by anchoring the NA cargo to the lipid bilayer membrane or by reducing the efficiency of annealing with the target molecule. To alleviate these effects, the cholesterol residue can be conjugated to the sense chain in siRNA, or it can be added through a cleavable arm, usually containing a disulfide bond (Boutorine and Kostina 1993; Chen et al. 2010; Manoharan et al. 2005; Moschos et al. 2007; Oberhauser and Wagner 1992) (Fig. 5).

The length of the linker can influence the cellular uptake; the optimal efficiency had been achieved for the RNA chain and the cholesterol residue spaced by 6–10 methylene units (Petrova et al. 2011). After penetration of the siRNA conjugates into cells, they affect the target gene expression, suggesting that they are able to escape from endosomes. So far, the mechanism of their endosomal release is still not understood, although it was hypothesized to be related to intracellular traffic of cholesterol (Maxfield and Wustner 2013).




Fig. 4 Cholesterol conjugated with oligonucleotides through branched linkers containing the following compounds: (a–c) glycerol, (d) 2-aminobutyl-1,3-propanediol, (e, f) L-hydroxyproline, (g) lysine, (h) serine, (i) serinol








Fig. 5 Cholesterol conjugated with oligonucleotides through various cleavable linkers containing disulfide bond

3 Modifications Improving the Stability of Nucleic Acids





After penetration in the cell and release into the cytoplasm, NA become vulnerable to nuclease attack. This complication can be circumvented if the oligonucleotide cargo is chemically modified to improve its stability. Chemical modifications of nucleic acids can be classified into three distinct categories: internucleoside linkage modifications, sugar modifications, and base modifications (the latter type can affect the thermal stability of the duplex but is not used for NA stabilization and is not considered here). The different types of modifications may be used within the same molecule, depending on the desired effect. We present the structure and the properties of the most used and promising modifications (Table 1).

Among oligonucleotide derivatives listed in Table 1, there are modifications, which are well known and have been recommended for therapeutic use; one can mention phosphorothioates, phosphorodiamidate morpholino oligomers (PMO), peptide nucleic acids (PNA), and different types of 2'-modified oligonucleotides

Table 1 Chemical modifications improving nucleic acids' stability






Modification	Structure	Properties	References
Modification of internucleoside link			
Phosphorothioate		Highly resistant to nuclease cleavage; decreases the duplex stability; binds to serum albumin; toxic	Bennett and Swayze (2010), Milligan et al. (1993)
N3' \rightarrow P5' Phosphorodiamidate morpholino oligomers (PMO)		Confers resistance to nucleases; increases T_m of duplex by 2 °C per residue for an RNA target	Gryaznov et al. (1995), Heidenreich et al. (1997)
Boranophosphate		Confers high nuclease resistance	Hall et al. (2004)
Amide-internucleosidic linkage		Confers nuclease resistance; leads to the duplex T_m change from -4 to +0.9 °C per residue for an RNA target	De Mesmaeker et al. (1994), Mutisya et al. (2014)

(continued)

Modification	Structure	Properties	References
Phosphonoacetate		Confers nuclease resistance; uncharged; decreases T_m of duplex by 1.2 °C per residue for an RNA target	Sheehan et al. (2003)
Morpholino		Highly resistant to nuclease cleavage; uncharged	Summerton and Weller (1997)
Peptide nucleic acid (PNA)		Highly resistant to nuclease cleavage; uncharged; increases T_m of duplex by 1 °C per residue for a DNA target	Shabi et al. (2006)
SATE (S-acyl-2-thioethyl-phosphotriesters)		Highly resistant to nuclease cleavage; uncharged; reversible protecting group (cleaved off by thioesterase in the cytoplasm)	Meade et al. (2014)



(continued)

Table 1 (continued)

Modification	Structure	Properties	References
Phosphoryl guanine (PG)		Highly resistant to nuclease cleavage; uncharged when fully modified	Kupryushkin et al. (2014), Lebedeva et al. (2015)
Sugar modifications			
2 ⁰ -OMe-RNA		Confers nuclease resistance; increases the duplex stability; decreases the innate immune response induction	Bennett and Swayzh (2010)
2 ⁰ -OMOE-RNA		Confers nuclease resistance; increases T _m of duplex by 2 °C per residue for an RNA target	
2 ⁰ F-RNA		Confers nuclease resistance; increases T _m of duplex by 2.2 °C per residue for an RNA target	Kawasaki et al. (1993)
Locked nucleic acid (LNA)		Confers nuclease resistance; increases T _m of duplex by 5.1 °C per residue for an RNA target and by 4 °C per residue for a DNA target	Koshkin et al. (1998)

(continued)

Table 1 (continued)

Modification	Structure	Properties	References
Unlocked nucleic acid (UNA)		Decreases T_m of duplex by 5–10 °C per residue for an RNA target and by 7–10 °C per residue for a DNA target	Campbell and Wengel (2011)
Xylo nucleic acid (XNA)		Confers nuclease resistance; decreases duplex stability	Poopeiko et al. (2003)

X—H (DNA) or OH (RNA); B—bases: A, C, G, T, U

(Wickstrom 2015). Another group consists of recently developed promising modifications of oligonucleotide structure whose potential should be studied in details in nearest future. Such modifications include amide-internucleosidic linkage, S-acyl-2-thioethyl-phosphotriesters (SATE), or phosphoryl guanidines (PG) incorporated instead of parent phosphodiester moieties. The derivatives and analogues listed in Table 1 can allow to design oligomers characterized by the electroneutral backbone, drastically increased nuclease resistance, and, therefore, enhanced therapeutic potential.

Modifications should be introduced with caution as they may change NA properties, such as toxicity and binding affinity for RNA/DNA targets. For instance, it was found that the increased amount of modified nucleotides enhanced the stability of siRNA in the presence of serum, but reduced its silencing activity. The targeted modification of nuclease-sensitive sites (mostly UpA, CpA, and UpG sites) improved the stability of siRNA and prolonged the silencing effect with minimal loss of silencing efficiency (Volkov et al. 2009). Moreover, 2'-O-methyl analogues of ribonucleotides introduced in the nuclease-sensitive sites of long dsRNA prevented the activation of innate immunity response without the loss of silencing efficiency and specificity (Gvozdeva et al. 2014).

4 Modifications of the Therapeutic RNA Imported into Human Mitochondria

Defects in human mitochondrial genome can cause a wide range of clinical disorders, mainly neuromuscular diseases. Most of deleterious mitochondrial mutations are heteroplasmic, meaning that wild-type and mutated forms of mtDNA coexist in the same cell (Pinto and Moraes 2014). Therefore, a shift in the proportion between mutant- and wild-type molecules could restore mitochondrial

functions. The anti-replicative strategy aims to induce such a shift in heteroplasmy by mitochondrial targeting specifically designed molecules in order to inhibit replication of mutant mtDNA. Recently, we developed mitochondrial RNA vectors (Kolesnikova et al. 2011) that can be used to address anti-replicative oligoribonucleotides into human mitochondria and impact heteroplasmy level. The observed effect was however transient, probably due to a rapid degradation of RNA molecules (Comte et al. 2013). Various chemically modified nucleotides have then been introduced in anti-replicative oligoribonucleotides to improve their stability, namely, nucleotides substituted at the 2'-hydroxyl group with 2'-OMe, 2'-F, and 2'-deoxy in combination with terminus capping chemistry. The most important increase of anti-replicative molecules' lifetime can be achieved by using synthetic RNA-DNA chimeric molecules or by ribose 2'-O-methylation in nuclease-sensitive sites. The presence of "inverted" 3'-3' thymidine at the 3'-terminus and modifications of 2'-OH ribose moiety did not prevent the mitochondrial uptake of the recombinant molecules. Nevertheless, the modified oligonucleotides did not cause a significant effect on the heteroplasmy level in transfected trans-mitochondrial cybrid cells bearing a pathogenic mtDNA deletion, proving to be less efficient than nonmodified RNA molecules (Tonin et al. 2014). One can hypothesize that the C3'-endo sugar conformation and 3'-3' inverted nucleotides might be recognized by the replisome or by other mitochondrial nucleoid proteins as nonnatural and quickly eliminated.

To decrease the toxicity of the cell transfection procedure and create an approach of carrier-free targeting of various anti-replicative RNAs into living human cells, we designed conjugates containing a cholesterol residue. Because cholesterol could stall the mitochondrial import of therapeutic anti-replicative RNA due to attachment to the mitochondrial membranes, we developed the protocol of chemical synthesis of oligoribonucleotides conjugated with cholesterol residue through cleavable covalent bonds. Conjugates containing pH-triggered hydrazone bond (Fig. 6a) were shown to be stable during the cell transfection procedure and rapidly cleaved in acidic endosomal cellular compartments. RNAs conjugated to cholesterol through a hydrazone bond were characterized by efficient carrier-free cellular uptake and partial co-localization with mitochondrial network. Moreover, the imported oligoribonucleotide designed to target a pathogenic point mutation in mitochondrial DNA was able to induce a decrease in the proportion of mutant mitochondrial genomes (Dovydenko et al. 2015).

We suppose that anti-replicative RNA conjugated to cholesterol can be internalized by the endocytosis pathway (Fig. 6b). Thereafter, the hydrazone bond between RNA and cholesterol moieties would be cleaved in the acidic conditions of the late endosomes, and the endosomal escape can be induced by destabilization of endosomal lipid bilayer, due to the positively charged hydrazide group which is formed by the conjugate hydrolysis. Released RNA molecules can be partially degraded in the cytoplasm, but still partially targeted into mitochondria due to the presence of a structural determinant for mitochondrial import.

To improve the in vivo delivery of cholesterol-RNA conjugates, we are planning to design and synthesize conjugated molecules containing various nucleotide and




Fig. 6 Cell delivery of RNA conjugated to cholesterol through cleavable linker. (a) Oligoribonucleotide conjugated with cholesterol residue through pH-triggered hydrazone bond. The point of the cleavage in acidic conditions is shown by an arrow. (b) Schematic representation of the cell delivery of RNA conjugated to cholesterol through cleavable linker. RNA is represented by a helix; cholesterol residue is highlighted in purple. See text for the details

internucleotide bond modifications, which can improve the stability of anti-replicative RNA moieties and promote their tissue distribution and cellular uptake.

5 Conclusion and Future Prospects

As one can deduce from the examples discussed above, there are various nucleotide modifications that can protect RNA molecules introduced into human cells against nucleolytic degradation. Another type of modification, the conjugation of oligonucleotides to the ligands, which can be internalized into the cell by natural transport mechanisms, is a promising approach to overcome the problem of their inefficient delivery to target cells and tissues. Further development of the oligonucleotide

modification technology will allow creating novel therapeutic molecules characterized by high stability, low toxicity, and efficient delivery to various human tissues.

Acknowledgments The authors are grateful to Prof. R. Afasizhev and Dr. A. Smirnov for the critical reading of the manuscript.

This work has been published under the framework of the LABEX ANR-11-LABX-0057_MITOCROSS and is supported by the state managed by the French National Research Agency as part of the Investments for the Future program. The work was also supported by CNRS (Centre National de Recherche Scientifique), University of Strasbourg and the LIA (International Associated Laboratory) ARN-mitocure. ID was supported by ARCUS-SUPRACHEM and MitoCross PhD fellowships.

References

- Aaldering LJ, Tayeb H, Krishnan S et al (2015) Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy. *RNA Biol* 12:412–425
- Balazs DA, Godbey W (2011) Liposomes for use in gene delivery. *J Drug Deliv* 2011:326497
- Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. *Annu Rev Pharmacol Toxicol* 50:259–293
- Bhat B, Balow G, Guzaev A et al (1999) Synthesis of fully protected nucleoside- folic acid conjugated phosphoramidites and their incorporation into antisense oligonucleotides. *Nucleosides Nucleotides* 18:1471–1472
- Biessen EA, Vietsch H, Rump ET et al (1999) Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. *Biochem J* 340(3):783–792
- Boisguerin P, Deshayes S, Gait MJ et al (2015) Delivery of therapeutic oligonucleotides with cell penetrating peptides. *Adv Drug Deliv Rev* 87:52–67
- Boutorine AS, Kostina EV (1993) Reversible covalent attachment of cholesterol to oligodeoxyribonucleotides for studies of the mechanisms of their penetration into eukaryotic cells. *Biochimie* 75:35–41
- Campbell MA, Wengel J (2011) Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. *Chem Soc Rev* 40:5680–5689
- Cesarone G, Edupuganti OP, Chen CP et al (2007) Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. *Bioconjug Chem* 18:1831–1840
- Chaltin P, Margineanu A, Marchand D et al (2005) Delivery of antisense oligonucleotides using cholesterol-modified sense dendrimers and cationic lipids. *Bioconjug Chem* 16:827–836
- Chen Q, Butler D, Querbes W et al (2010) Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. *J Control Release* 144:227–232
- Comte C, Tonin Y, Heckel-Mager AM et al (2013) Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre Syndrome. *Nucleic Acids Res* 41:418–433
- Davydova AS, Vorobjeva MA, Venyaminova AG (2011) Escort aptamers: new tools for the targeted delivery of therapeutics into cells. *Acta Nat* 3:12–29
- De Haes W, Van Mol G, Merlin C et al (2012) Internalization of mRNA lipoplexes by dendritic cells. *Mol Pharm* 9:2942–2949
- De Mesmaeker A, Lebreton J, Waldner A et al (1994) Replacement of the phosphodiester linkage in oligonucleotides: comparison of two structural amide isomers. *Bioorg Med Chem Lett* 4:873–878

- DiFiglia M, Sena-Esteves M, Chase K et al (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. *Proc Natl Acad Sci USA* 104:17204–17209
- Dizaj SM, Jafari S, Khosroushahi AY (2014) A sight on the current nanoparticle-based gene delivery vectors. *Nanoscale Res Lett* 9:252
- Dovydenko I, Tarassov I, Venyaminova A et al (2015) Method of carrier-free delivery of therapeutic RNA importable into human mitochondria: lipophilic conjugates with cleavable bonds. *Biomaterials* 76:408–417
- Ginn SL, Alexander IE, Edelstein ML et al (2013) Gene therapy clinical trials worldwide to 2012: an update. *J Gene Med* 15:65–77
- Gryaznov SM, Lloyd DH, Chen JK et al (1995) Oligonucleotide N3⁰–P5⁰ phosphoramidates. *Proc Natl Acad Sci USA* 92:5798–5802
- Guzaev AP, Cook PD, Manoharan M et al (2002) Nucleosidic and non-nucleosidic folate conjugates. ISIS Pharmaceuticals Inc. US Patent 6,335,434 B1: 84
- Gvozdeva OV, Dovydenko IS, Venyaminova AG et al (2014) 42- and 63-bp anti-MDR1-siRNAs bearing 2⁰-OME modifications in nuclease-sensitive sites induce specific and potent gene silencing. *FEBS Lett* 588:1037–1043
- Hall AH, Wan J, Shaughnessy EE et al (2004) RNA interference using boranophosphate siRNAs: structure-activity relationships. *Nucleic Acids Res* 32:5991–6000
- Heidenreich O, Gryaznov S, Nerenberg M (1997) RNase H-independent antisense activity of oligonucleotide N3⁰–P5⁰ phosphoramidates. *Nucleic Acids Res* 25:776–780
- Huotari J, Helenius A (2011) Endosome maturation. *Embo J* 30:3481–3500
- Juliano R, Alam MR, Dixit V et al (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. *Nucleic Acids Res* 36:4158–4171
- Juliano R, Bauman J, Kang H et al (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. *Mol Pharm* 6:686–695
- Juliano RL, Carver K, Cao C et al (2013) Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. *J Drug Target* 21:27–43
- Kawasaki AM, Casper MD, Freier SM et al (1993) Uniformly modified 2⁰-deoxy-2⁰-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. *J Med Chem* 36:831–841
- Kay MA (2011) State-of-the-art gene-based therapies: the road ahead. *Nat Rev Genet* 12:316–328
- Kolesnikova O, Kazakova H, Comte C et al (2011) Selection of RNA aptamers imported into yeast and human mitochondria. *RNA* 16:926–941
- Koshkin AA, Singha SK, Nielsen P et al (1998) LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. *Tetrahedron* 54:3607–3630
- Kubo T, Zhelev Z, Ohba H et al (2007) Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. *Oligonucleotides* 17:445–464
- Kupryushkin MS, Pyshnyi DV, Stetsenko DA (2014) Phosphoryl guanidines: a new type of nucleic acid analogues. *Acta Nat* 6:116–118
- Lebedeva NA, Anarbaev RO, Kupryushkin MS et al (2015) Design of a new fluorescent oligonucleotide-based assay for a highly specific real-time detection of apurinic/apyrimidinic site cleavage by tyrosyl-DNA phosphodiesterase 1. *Bioconj Chem* 26:2046–2053
- Letsinger RL, Zhang GR, Sun DK et al (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. *Proc Natl Acad Sci USA* 86:6553–6556
- Lorenz C, Hadwiger P, John M et al (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. *Bioorg Med Chem Lett* 14:4975–4977
- MacKellar C, Graham D, Will DW et al (1992) Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. *Nucleic Acids Res* 20:3411–3417

- Manoharan M, Kesavan V, Rajeev KG (2005) Modified iRNA agents. Fish and Richardson Paper Corporation Boston MA. 20050107325 A1, USA, pp 245
- Maxfield FR, Wustner D (2013) Analysis of cholesterol trafficking with fluorescent probes. *Methods Cell Biol* 108:367–393
- McGuire MJ, Gray BP, Li S et al (2014) Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. *Sci Rep* 4:4480
- Meade BR, Gogoi K, Hamil AS et al (2014) Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. *Nat Biotechnol* 32:1256–1261
- Milligan JF, Matteucci MD, Martin JC (1993) Current concepts in antisense drug design. *J Med Chem* 36:1923–1937
- Ming X, Laing B (2015) Bioconjugates for targeted delivery of therapeutic oligonucleotides. *Adv Drug Deliv Rev* 87:81–89
- Ming X, Alam MR, Fisher M et al (2010) Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. *Nucleic Acids Res* 38:6567–6576
- Moschos SA, Jones SW, Perry MM et al (2007) Lung delivery studies using siRNA conjugated to TAT (48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. *Bioconjug Chem* 18:1450–1459
- Mutisya D, Selvam C, Lunstad BD et al (2014) Amides are excellent mimics of phosphate internucleoside linkages and are well tolerated in short interfering RNAs. *Nucleic Acids Res* 42:6542–6551
- Nair JK, Willoughby JL, Chan A et al (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. *J Am Chem Soc* 136:16958–16961
- Oberhauser B, Wagner E (1992) Effective incorporation of 2^l-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol. *Nucleic Acids Res* 20:533–538
- Oliveira C, Silveira I, Veiga F et al (2015) Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance. *Expert Opin Drug Deliv* 12:27–39
- Petrova NS, Chernikov IV, Meschaninova MI et al (2011) Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. *Nucleic Acids Res* 40:2330–2344
- Pinto M, Moraes CT (2014) Mitochondrial genome changes and neurodegenerative diseases. *Biochim Biophys Acta* 1842:1198–1207
- Poopeiko NE, Dahl BM, Wengel J (2003) Xylo-configured oligonucleotides (XNA, xylo nucleic acids): synthesis and hybridization studies. *Nucleosides Nucleotides Nucleic Acids* 22:1147–1149
- Prakash TP, Graham MJ, Yu J et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. *Nucleic Acids Res* 42:8796–8807
- Raouane M, Desmaele D, Urbinati G et al (2012) Lipid conjugated oligonucleotides: a useful strategy for delivery. *Bioconjug Chem* 23:1091–1104
- Reed MW, Adams AD, Nelson JS et al (1991) Acridine- and cholesterol-derivatized solid supports for improved synthesis of 3^l-modified oligonucleotides. *Bioconjug Chem* 2:217–225
- Rump ET, de Vruh RL, Slidregt LA et al (1998) Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein. *Bioconjug Chem* 9:341–349
- Seo YJ, Jeong HS, Bang EK et al (2006) Cholesterol-linked fluorescent molecular beacons with enhanced cell permeability. *Bioconjug Chem* 17:1151–1155
- Shabi S, Sajjad K, Arif A (2006) Peptide nucleic acid (PNA): a review. *J Chem Technol Biotechnol* 81:892–899

- Sheehan D, Lunstad B, Yamada CM et al (2003) Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. *Nucleic Acids Res* 31:4109–4118
- Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* 432:173–178
- Stetsenko DA, Gait MJ (2001) A convenient solid-phase method for synthesis of 3'-conjugates of oligonucleotides. *Bioconjug Chem* 12:576–586
- Stockert RJ (1995) The asialoglycoprotein receptor: relationships between structure, function, and expression. *Physiol Rev* 75:591–609
- Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. *Antisense Nucleic Acid Drug Dev* 7:187–195
- Tan W, Wang H, Chen Y et al (2011) Molecular aptamers for drug delivery. *Trends Biotechnol* 29:634–640
- Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. *Nat Rev Genet* 4:346–358
- Tonin Y, Heckel AM, Dovydenco I et al (2014) Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA. *Biochimie* 100:192–199
- Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* 249:505–510
- Uckun FM, Qazi S, Dibirdik I et al (2013) Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia. *Integr Biol (Camb)* 5:122–132
- Ueno Y, Kawada K, Naito T et al (2008) Synthesis and silencing properties of siRNAs possessing lipophilic groups at their 3'-termini. *Bioorg Med Chem* 16:7698–7704
- Varkouhi AK, Scholte M, Storm G et al (2011) Endosomal escape pathways for delivery of biologicals. *J Control Release* 151:220–228
- Vives E, Schmidt J, Pelegrin A (2008) Cell-penetrating and cell-targeting peptides in drug delivery. *Biochim Biophys Acta* 1786:126–138
- Volkov AA, Kruglova NS, Meschaninova MI et al (2009) Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. *Oligonucleotides* 19:191–202
- Vu H, Singh P, Joyce N et al (1993) Synthesis of cholesteryl supports and phosphoramidites containing a novel peptidyl linker for automated synthesis of triple-helix forming oligonucleotides (TFOs). *Nucleic Acids Symp Ser*:19–20
- Walther W, Stein U (2000) Viral vectors for gene transfer: a review of their use in the treatment of human diseases. *Drugs* 60:249–271
- Wickstrom E (2015) DNA and RNA derivatives to optimize distribution and delivery. *Adv Drug Deliv Rev* 87:25–34
- Winkler J (2013) Oligonucleotide conjugates for therapeutic applications. *Ther Deliv* 4:791–809
- Wolfrum C, Shi S, Jayaprakash KN et al (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. *Nat Biotechnol* 25:1149–1157
- Zhou J, Rossi JJ (2011) Cell-specific aptamer-mediated targeted drug delivery. *Oligonucleotides* 21:1–10